NeuroBo Pharmaceuticals, Inc. (NRBO)

NeuroBo Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	6.82	6.73	8.64	8.75	7.85	2.7
Research & Development	13.43	9.16	2.78	6.55	4.53	5.32
Other Operating Expenses	0	0	8.21	0	17.34	12.15
Operating Expenses	20.25	15.89	19.63	15.3	29.72	20.18
Operating Income	-20.25	-15.89	-19.63	-15.3	-29.72	-20.18
Interest Expense / Income	0	0	2.19	0	0	0.02
Other Expense / Income	-3.67	-3.42	-7.85	-0.01	-0.04	1.11
Pretax Income	-16.58	-12.47	-13.97	-15.28	-29.68	-21.31
Net Income	-16.58	-12.47	-13.97	-15.28	-29.68	-21.31
Shares Outstanding (Basic)	5	5	0	0	0	0
Shares Outstanding (Diluted)	5	5	0	0	0	0
Shares Change	0.60%	1476.33%	233.62%	42.72%	210.43%	22.88%
EPS (Basic)	-3.22	-2.46	-43.42	-158.48	-439.24	-979.30
EPS (Diluted)	-3.22	-2.46	-43.42	-158.48	-439.24	-979.30
Free Cash Flow	-14.75	-10.85	-11.7	-15.14	-10.77	-7.25
Free Cash Flow Per Share	-2.90	-2.14	-36.38	-156.98	-159.37	-333.24
EBITDA	-16.57	-12.46	-11.75	-15.21	-29.61	-21.27
Depreciation & Amortization	0.01	0.01	0.03	0.07	0.07	0.02
EBIT	-16.58	-12.47	-11.78	-15.28	-29.68	-21.29

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).